Business Development at Agios
Our robust research engine is only the beginning. Agios actively seeks external opportunities and partnerships with companies and academic institutions around the globe.
Why Partner With Us
The core of Agios remains our research engine, from a robust discovery toolkit to a focus on the deep biological interrogation of prospective targets and mechanisms of action. Translational thinking is embedded across programs early in research, to ensure a rapid and successful transition to the clinic. Once in the clinic, we embrace trial designs that allow for rapid clinical proof of concept, guiding the subsequent development path. We are committed to leveraging our established and growing commercial presence to both deliver medicines to patients worldwide and maximize value for Agios and its partners. Across all functions and stages of development, Agios embraces its “Other Side of Possible” (OSOP) culture to accomplish the extraordinary while prioritizing the patients whom we seek to serve.
Agios as a Partner of Choice
Agios research established for the first time that the mutated metabolic gene IDH1 has novel enzymatic activity consistent with an oncogene. This scientific insight drove first-in-class drug discovery and development of ivosidenib and enasidenib, inhibitors of mutant IDH1 and mutant IDH2 enzymes, respectively.
Agios developed and validated measurement of 2-HG to allow for rapid evaluation of mutant IDH target engagement and dose selection.
Rapid transition of Phase 1 dose-escalation study of IDH inhibitors in hematologic malignancies into expansion cohorts to drive interrogation of early efficacy in acute myeloid leukemia (AML). Early assessment of proof of concept in single-arm studies led to FDA full approval in relapsed or refractory AML with mutant IDH1 or mutant IDH2 enzyme.
Robust and continuous teamwork across internal functions and close collaboration with academia and clinical investigators throughout early research to late-stage development.
Learn more about Agios’ business development focus:
First-in-class, first-in-disease or best-in-class with meaningful differentiation and high unmet medical need.
Assets in all stages from early discovery to commercial, however assets from Lead Optimization through Phase 1 are in our sweet spot
Small molecule programs irrespective of stage, other modalities after selection of a candidate to start IND enabling studies.
Flexible with a focus on collaboration structures that leverage the strengths of each party to maximize patient access and asset value.
In April 2010, Agios and Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, entered into a global strategic collaboration focused on cancer metabolism. This collaboration led to two approved medicines, IDHIFA® (enasidenib) and TIBSOVO® (ivosidenib tablets), and one clinical candidate, vorasidenib, currently in Phase 3 development for low-grade glioma. Under the terms of the agreement, Celgene has worldwide development and commercialization rights for IDHIFA®. Agios continues to conduct certain clinical development activities within the IDHIFA® development program and is eligible to receive reimbursement for those development activities and up to $80 million in remaining milestone payments, and royalties on any net sales. Celgene and Agios are currently co-commercializing IDHIFA® in the U.S. Celgene will reimburse Agios for costs incurred for its co-commercialization efforts. TIBSOVO® and vorasidenib are wholly owned by Agios.
In May 2018, Agios and CStone Pharmaceuticals announced an exclusive collaboration and license agreement for the development and commercialization of ivosidenib (TIBSOVO®) in Mainland China, Hong Kong, Macau and Taiwan.
In April 2017, Agios and Aurigene Discovery Technologies Limited entered into a global license agreement to research, develop and commercialize small molecule inhibitors of dihydroorotate dehydrogenase (DHODH).
In Oct. 2016, Agios entered into a collaboration agreement with Abbott (NYSE: ABT) to develop and commercialize a companion diagnostic test on Abbott’s m2000 RealTime System to identify isocitrate dehydrogenase 1 (IDH1) mutations in acute myeloid leukemia (AML) patients.
In May 2017, Agios entered into a development agreement with Thermo Fisher Scientific for a next-generation sequencing oncology companion diagnostic to identify isocitrate dehydrogenase 1 (IDH1) mutations in cholangiocarcinoma patients.